Novo Nordisk Shifts Strategy with Affordable Weight-Loss Pill Launch

In a bold move to capture broader market share, Novo Nordisk has initiated a significant strategic pivot in the lucrative weight-loss drug sector. The Danish pharmaceutical giant is now introducing a far more affordable oral version of its Wegovy treatment to U.S. pharmacies, marking a departure from its previous reliance on high-margin injectable therapies. This calculated shift toward the mass market aims to secure decisive ground before competitors can respond.

The oral Wegovy formulation became available across approximately 70,000 U.S. pharmacies starting January 5, 2026. Its aggressive pricing structure is a central feature of the launch: the entry-level dose is priced at $149 per month for self-paying patients, with the maintenance dose set at Read more...